• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

M&A, asset sales and spin-offs in pharmaceutical and medical device industries

Share:

May 9, 2018

Highlights on this story:
  • A marketing authorisation is a permit or licence granted by the authorities which allows a specific legal entity to market a product in Mexico, subject to the requirements therein.
  • A marketing authorisation is not an asset that is subject to an asset transfer. Rather, it is issued to a specific individual or legal entity that is thereby permitted to import, store, distribute, sell and carry out any kind of act involving a specific product.

Mergers and acquisitions (M&A), asset sales, spin-offs and similar activities in the pharmaceutical, medical device and other health-related industries were abundant in 2016 and 2017. For example, many companies:

  • acquired competitors or device companies;
  • merged;
  • separated business lines; or
  • spun-off or acquired smaller specialised companies or specific assets.

In addition, there was a notable increase in the participation of smaller specialised companies in niche areas of these industries, as well as the number of companies engaged in the necessary raw material, ingredient, chemical, controlled substance and additive sectors.

Mexico is the second largest market for the pharmaceutical and medical device industries in Latin America. Thus, as the above activities are often global or at least multinational, they often affect companies that operate in Mexico. Companies carrying out business in the life sciences sector, particularly the pharmaceutical and medical device industries, should therefore consider how global or regional reorganisations, M&A, spin-offs or similar activities will affect their operations in the Mexican market. Although there have been many unfortunate situations where such activities have been delayed or cancelled, this can be avoided by undertaking appropriate legal due diligence and seeking advice.

Marketing authorisations

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

A common barrier in this regard concerns the transfer of a marketing authorisation or sanitary registration to the new entity in charge of the relevant operations in Mexico. This is particularly risky where goods are imported, manufactured or marketed in Mexico and a transfer of operations to a multinational may result in a change of:

  • the raw materials or manufacturing processes used to make goods;
  • product names;
  • the origin of goods; or
  • any other information originally submitted to the Mexican health authorities.

Although mergers and spin-offs theoretically involve the transfer of all or part of a legal entity’s assets to another entity, these assets do not include the corresponding marketing authorisations or sanitary registrations from the health authorities.

A marketing authorisation is a permit or licence granted by the authorities which allows a specific legal entity to market a product in Mexico, subject to the requirements therein. Holders of marketing authorisations must duly evidence proper compliance with the applicable requirements and provide certain information. A marketing authorisation is not an asset that is subject to an asset transfer. Rather, it is issued to a specific individual or legal entity that is thereby permitted to import, store, distribute, sell and carry out any kind of act involving a specific product.

In the case of a merger, acquisition, spin-off or similar activity, a marketing authorisation concerning a pharmaceutical or medical device is not automatically transferred. Since the acquirer will be a different legal entity to that which was awarded the authorisation, the health authorities can question and even impede such a transfer.

Although an official assignment procedure is outlined in the health regulations, in practice, the original holder must refile most of the information initially required for the marketing authorisation’s issuance. These authorisations may take several months (and sometimes years) to be completed. Due to their specific nature, it is impossible to guarantee that the authorities will grant the authorisations without additional requirements. Likewise, any change in the manufacturing processes or facts on which a marketing authorisation was granted may be deemed a change in conditions and thus a reason for its cancellation.

Further, in some cases, a marketing authorisation already held by a purchasing company can prevent the acquisition of a separate one. This is due to various prohibitions in Mexican law regarding multiple authorisations for the same product.

Date: April 25, 2018

Source: InternationalLawOffice

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • 10 Best Life Sciences Stocks for This Year – Top Stocks – TheStreet Ratings10 Best Life Sciences Stocks for This Year – Top Stocks – TheStreet Ratings
  • Folx Health Scores $30M to Add Mental Health SupportFolx Health Scores $30M to Add Mental Health Support
  • Genesis MedTech Acquires World-first Drug-coated Balloon Technology with Next-generation Angioplasty Architecture for the Treatment of Peripheral Vascular DiseasesGenesis MedTech Acquires World-first Drug-coated Balloon Technology with Next-generation Angioplasty Architecture for the Treatment of Peripheral Vascular Diseases
  • BillionToOne Raises $125M to Expand Genetic Testing PlatformBillionToOne Raises $125M to Expand Genetic Testing Platform
  • P4 Diagnostix® Announces Acquisition of Strand Diagnostics and know error®P4 Diagnostix® Announces Acquisition of Strand Diagnostics and know error®
  • Teladoc Health Completes Merger with LivongoCombination Creates the Global Leader in Whole-Person Virtual CareTeladoc Health Completes Merger with LivongoCombination Creates the Global Leader in Whole-Person Virtual Care
  • Binah.ai Rolls Out New Contactless Blood-pressure-monitoring SystemBinah.ai Rolls Out New Contactless Blood-pressure-monitoring System
  • Worst Deal Ever? Bayer’s Market Cap Now Close To The Total Cost It Paid For Monsanto

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications